Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Spriggs

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
Infection and Immunity|January 1, 1974
Role of mycobactin in the growth and virulence of tubercle bacilliC A Golden, I Kochan, D R Spriggs
Oncology Research|January 1, 1995
Possible correlation between ormaplatin biotransformations and neurotoxicityM Sakata, S G Chaney, D R Spriggs
Clinics in Haematology|November 1, 1986
The treatment of myelodysplastic syndromesD R Spriggs, R M Stone, D W Kufe
Current Treatment Options in Oncology|June 12, 2002
New drugs in gynecologic cancerA Daud, P Munster, P Munster, et al.
Seminars in Oncology|June 1, 1987
Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinosideD W Kufe, D R Spriggs, J D Griffin
Journal of Virology|November 1, 1980
BALB/c myeloma retroviruses have mink cell focus-inducing activityD R Spriggs, M A Diebold, R G Krueger
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 14, 2005
New agents for the treatment of ovarian cancer: the next generationJ Dupont, C Aghajanian, P Sabbatini, et al.
Science (New York, N.Y.)|April 29, 1983
Hemagglutinin variants of reovirus type 3 have altered central nervous system tropismD R Spriggs, R T Bronson, B N Fields
Virology|February 1, 1982
Evidence for functional domains on the reovirus type 3 hemagglutininS J Burstin, D R Spriggs, B N Fields
Seminars in Oncology|June 1, 1985
Cellular and clinical pharmacology of low-dose ara-CD W Kufe, J D Griffin, D R Spriggs
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Infection and Immunity|January 1, 1974
Role of mycobactin in the growth and virulence of tubercle bacilliC A Golden, I Kochan, D R Spriggs
Oncology Research|January 1, 1995
Possible correlation between ormaplatin biotransformations and neurotoxicityM Sakata, S G Chaney, D R Spriggs
Clinics in Haematology|November 1, 1986
The treatment of myelodysplastic syndromesD R Spriggs, R M Stone, D W Kufe
Current Treatment Options in Oncology|June 12, 2002
New drugs in gynecologic cancerA Daud, P Munster, P Munster, et al.
Seminars in Oncology|June 1, 1987
Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinosideD W Kufe, D R Spriggs, J D Griffin
Journal of Virology|November 1, 1980
BALB/c myeloma retroviruses have mink cell focus-inducing activityD R Spriggs, M A Diebold, R G Krueger
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 14, 2005
New agents for the treatment of ovarian cancer: the next generationJ Dupont, C Aghajanian, P Sabbatini, et al.
Science (New York, N.Y.)|April 29, 1983
Hemagglutinin variants of reovirus type 3 have altered central nervous system tropismD R Spriggs, R T Bronson, B N Fields
Virology|February 1, 1982
Evidence for functional domains on the reovirus type 3 hemagglutininS J Burstin, D R Spriggs, B N Fields
Seminars in Oncology|June 1, 1985
Cellular and clinical pharmacology of low-dose ara-CD W Kufe, J D Griffin, D R Spriggs
Pageof 10